Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Sponsor: Medivation, Inc.
Listed as NCT01286987, this PHASE1 trial focuses on Advanced or Recurrent Solid Tumors and Breast Neoplasms and remains completed. Sponsored by Medivation, Inc., it has been updated 9 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Aug 2017 — Sep 2017 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medivation, Inc.
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .